Print
Email
Print Edition StoriesWednesday, June 3, 2009
Ascent Therapeutics adds Tagliamonte, Houston to exec roles
By Mass High Tech staff
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
Ascent Therapeutics Inc. has appointed John Tagliamonte to the position of vice president of business development and Michael Houston to the role of vice president for preclinical chemistry, and chemistry manufacture and control.
Tagliamonte joins Ascent having previously served as vice president of business development for ImmunoGen Inc. Prior to that role, he worked on venture investments for two years at Safeguard Scientifics Inc. and held the interim head of business development position at Laureate Pharma. He also served as director of strategy and business development at Johnson & Johnson Co.
Tagliamonte graduated from Boston College with a master’s degree in business administration and bachelor of science degree in molecular biology from Tufts University.
Houston joins Ascent having worked previously for MDRNA Inc. as vice president of chemistry and formulations. He has also served as senior director of chemistry at Nastech Pharmaceutical Company Inc. (before it became MDRNA) and as director of chemistry at Cytovax Biotechnologies Inc.
Houston received his doctorate degree from the University of Waterloo and held a post-doctoral fellowship at the University of Alberta.
Ascent is a biopharmaceutical company working on a new class of biologics targeting G-protein coupled receptors (GPCRs), one of the most common targets of currently approved drugs, the company said. Ascent will discover and develop drug candidates against a specific GPCR target using its Pepducin platform.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.